AddedRisk Factors
As we are initially seeking to identify and develop product candidates to treat diseases using novel technologies, there is heightened risk that the FDA, the EMA or other regulatory authority may not consider the clinical trial endpoints that we propose to provide clinically meaningful results. Even if the endpoints are deemed clinically meaningful, we may not achieve these endpoints to a degree
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedRisk Factors
For example, on September 9, 2025, the President issued a memorandum directing HHS to “ensure transparency and accuracy in DTC prescription drug advertising, including by increasing the amount of information regarding any risks associated with the use of any
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedRisk Factors
such prescription drug required to be provided in prescription drug advertisements.” To that end, the FDA announced that it is initiating a rulemaking process “to eliminate the ‘adequate provision’ loophole that allows pharmaceutical advertisements to hide safety information by placing it in another format or location.” In this context, the FDA declared that it will no longer tolerate what it characterized as “deceptive practices” in prescription drug advertising and that the FDA would “aggressively deploy” its available enforcement tools, with “heightened scrutiny” of fair balance and disclosures in social media promotions. The FDA also issued a generic “notice letter” directing companies to “remove any noncompliant advertising and bring all promotional communications into compliance.”
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedRisk Factors
promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RemovedRisk Factors
In September 2022, we helped launch Orbital Therapeutics Inc., or Orbital, in collaboration with ARCH Venture Partners, with a goal of advancing ribonucleic acid, or RNA, medicines. In connection with the Orbital launch, we entered into a license and collaboration agreement, or the Orbital Agreement, with Orbital pursuant to which we and Orbital each granted the other licenses to certain technology controlled by it necessary or reasonably useful for the non-viral delivery or the design or manufacture of RNA for the prevention, treatment or diagnosis of human disease. In addition, concurrently with our entry into the Orbital Agreement, Orbital issued us 75 million shares of its common stock. ARCH Venture Partners is also a stockholder of Orbital, one of our directors affiliated with ARCH Venture Partners, John Maraganore, as well as John Evans, our Chief Executive Officer, are members of the board of directors of Orbital.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
We have a lesser degree of control over its business operations, thereby potentially subjecting us to additional financial, legal, operational and compliance risks. In addition, the controlling shareholders or management of Orbital may have business interests, strategies or goals that are inconsistent with ours. These risks include the possibility that Orbital or such other stockholders have economic or business interests or goals that are or become inconsistent with our economic or business interests or goals; are in a position to take action contrary to our instructions, requests, policies or objectives; subject us to unexpected liabilities or risks; take actions that reduce our return on investment; act in a manner that compromises our key licensed rights, or important intellectual or other rights that we own or license; or take actions that harm our reputation or restrict our ability to run our business. Furthermore, as a result of our ownership in Orbital, we may in the future be required to include Orbital’s financial information in our consolidated financial results. We have not previously included a minority-owned subsidiary in our financial statements and we would therefore be subject to increased risk in accurately representing and incorporating Orbital financial statements into our own, which could result in delayed filings with the SEC and the finding of a material or significant weakness, among others. This could result in harmful consequences to our business, including an adverse reaction in the financial markets due to a loss of confidence in the reliability of our consolidated financial statements.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
additional uncertainty into the regulatory process and may result in additional legal challenges to actions taken by federal regulatory agencies, including the FDA and CMS, that we rely on. In addition to potential changes to regulations as a result of legal challenges, these decisions may result in increased regulatory uncertainty and delays and other impacts, any of which could adversely impact our business and operations.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
Recent changes or future changes in tax law may adversely affect our business or financial condition. On December 22, 2017, the Tax Act was signed into law. The Tax Act, as amended by the CARES Act, among other things, contains significant changes to corporate taxation, including the reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% and, for taxable years beginning after December 31, 2020, the limitation of the deduction for net operating losses to 80% of current year taxable income in respect of net operating losses generated during or after 2018. Any federal net operating loss incurred in 2018 and in future years may now be carried forward indefinitely pursuant to the Tax Act, but can no longer be carried back. Similar rules and limitations may apply for state income tax proposes. In addition, beginning in 2022, the Tax Act eliminates the option to deduct research and development expenditures currently and generally requires corporations to capitalize and amortize them over five years (or 15 years for expenditures attributable to foreign research).
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RewordedRisk Factors
If any product candidates we develop are associated with serious adverse events, undesirable side effects, or unexpected characteristics, we may need to abandon their development or limit development to certain uses or subpopulations in which the serious adverse events, undesirable side effects or other characteristics are less prevalent, less severe, or more acceptable from a risk-benefit perspective, any of which would have a material adverse effect on our business, financial condition, results of operations, and prospects.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, if patients are unwilling to participate in our base editing trials because of negative publicity from adverse events related to the biotechnology, gene therapy, or gene editing fields, competitive clinical trials for similar patient populations, clinical trials in competing products, or for other reasons, the timeline for recruiting patients, conducting studies, and obtaining regulatory approval of any product candidates we may develop
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Even after we receive and incorporate guidance from these regulatory authorities, the FDA, European national competent authority, or other regulatory authorities could disagree that we have satisfied their requirements to commence our clinical trial or change their position on the acceptability of our data, trial design or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials or impose stricter requirements for approval than we currently expect.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we or our licensors are unsuccessful in any interference proceedings or other priority, validity (including any patent oppositions), or inventorship disputes to which we or they are subject, we may lose valuable intellectual property rights through the loss of one or more of our owned, licensed, or optioned patents, or such patent claims may be narrowed, invalidated, or held unenforceable, or through loss of exclusive ownership of or the exclusive right to use our owned or in-licensed patents. patents (for example, European Patent No.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Violation of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, Washington state passed a health privacy law the My Health My Data Act in 2023 that specifically regulates the collection and sharing of health information, and the law also has a private right of action, which further increases the relevant compliance risk.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Debt financing, if available, may involve agreements that include Our financing agreement with Sixth Street Lending Partners includes covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends, and possibly other restrictions, and future debt financings may contain similar restrictions.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, in October 2023, we implemented a strategic restructuring to prioritize development of our ex vivo and in vivo sickle cell disease programs, including BEAM-101, our ESCAPE conditioning strategy, and in vivo delivery to hematopoietic stem cells program, as well as our in vivo base editor BEAM-302 in development for the treatment of alpha-1 antitrypsin deficiency. BEAM-302.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Failure to comply with laws regarding data protection would expose us to risk of enforcement actions taken by data protection authorities in the EEA and elsewhere and carries with it the potential for significant penalties if we are found to be non-compliant.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
The prices of these ten drugs will become became effective January 1, 2026.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
December 2025. The U.S. Food and Drug Administration, or the FDA, has granted orphan drug designation and regenerative medicine advanced therapy designation to risto-cel. Risto-cel has also been accepted into the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness pilot program.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
In December 2025, we presented updated data from the BEACON trial at the American Society of Hematology 2025 Annual Meeting, or ASH. The presentation contained preliminary data as of August 6, 2025, from 31 patients in the trial, with follow up ranging from 0.3 to 20.4 months. The presentation data included the following:
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
•Patients achieved mean HbF levels above 60% and a mean durable reduction in corresponding HbS below 40%. A pancellular distribution of HbF, reflecting expression across most of the circulating red blood cells, was observed, with mean per-cell HbF levels maintained above the sickling threshold throughout follow-up. Durable, high editing efficiency was observed in peripheral blood and bone marrow following treatment with risto-cel. Mean peripheral blood editing was 67.4% at Month 6 and 72.8% by Month 12
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
•Patients required a median of one (range: 1-5) stem cell collection cycle, comprising a median of three (range: 1–13) total collection days for the risto-cel manufacturing process and back-up cell collection. The median time to neutrophil engraftment was 17.5 days (range: 12-30), with a median duration of severe neutropenia of seven days (range: 1-17). The median time to platelet engraftment was 19 days (range: 11-53). In addition, 29% of patients did not require any platelet transfusions following risto-cel treatment.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
•Total Hb levels increased rapidly with all patients experiencing resolution of anemia after elimination of the transfused blood. Key markers of hemolysis, including indirect bilirubin, haptoglobin, lactate dehydrogenase, and reticulocytes, normalized or improved in all patients following risto-cel treatment. Erythropoietin levels also trended toward normal, indicating significant improvement in oxygen delivery to tissues. Sickling parameters all decreased in the blood following risto-cel treatment to levels comparable to those seen in individuals with sickle cell trait.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
•The initial safety profile of risto-cel was consistent with busulfan conditioning, autologous HSCT and underlying sickle cell disease. The most common treatment-emergent adverse events were consistent with busulfan conditioning, including febrile neutropenia, stomatitis and decreased appetite. As previously reported, one patient died four months after risto-cel infusion due to respiratory failure that was determined by the investigator to be likely related to busulfan conditioning and deemed unrelated to risto-cel. No patients experienced any investigator-reported severe vaso-occlusive crises post-engraftment.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
We continue to develop targeted LNPs for the in vivo delivery of gene editing payloads to HSCs. Based on recent advancements in this technology, we are now prioritizing in vivo delivery for our next wave approach to treating sickle cell disease. We have identified multiple targeted LNPs that have the potential for HSC delivery and are currently engaged in lead optimization. In parallel, we are also continuing development of our proprietary ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. ESCAPE has the potential to enable non-genotoxic treatment strategies that can be delivered either ex vivo or in vivo, including as part of any future in vivo program for sickle cell disease. We are conducting a Phase 1 healthy volunteer clinical trial of BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE, and expect to complete dosing in the trial in the first half of 2026.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Updated clinical data from the dose-escalation portions of Part A and Part B are expected to be shared in the first quarter of 2026, along with an updated clinical development plan for BEAM-302 in patients with AATD. We expect to finalize dose selection for registrational development based on the totality of data from the BEAM-302 trial. We have reached alignment with the FDA on a potential accelerated approval pathway for BEAM-302 based on AAT biomarkers evaluated over 12 months. To support a future BLA submission, we anticipate enrolling approximately 50 additional patients to be treated with the selected optimal biological dose of BEAM-302 in an expansion of the ongoing Phase 1/2 clinical trial.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
BEAM-304 is a newly announced liver-targeting LNP formulation of base editing reagents designed to correct disease-causing mutations responsible for phenylketonuria, or PKU. PKU is an autosomal recessive disorder caused by mutations in the phenylalanine hydroxylase, or PAH, gene that prevents the body from metabolizing the amino acid phenylalanine, or Phe. Elevated levels of Phe may result in severe neurological and neurocognitive impairments. Patients are generally identified via newborn screening, with the standard of care involving a Phe-restricted diet, as well as medicines that manage Phe levels. Initially, we plan to develop BEAM-304 for the treatment of the two most prevalent variants found in PKU patients in the United States, with ongoing research effort to address the majority of the remaining mutations. In preclinical studies, administration of BEAM-304 resulted in the normalization of Phe levels in mice at therapeutically relevant doses, even when consuming a standard diet. In 2026, we plan to submit a regulatory application for authorization to initiate an open-label, dose-ascending, Phase 1/2 trial of BEAM-304 in PKU patients with the R408W mutation. We believe that learnings from this trial have the potential to provide a predictable path to accelerated development of BEAM-304 for additional mutations, including as a result of novel FDA frameworks for platform medicines.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
On February 24, 2026, or the Closing Date, we entered into a financing agreement, or the Financing Agreement, with certain of our subsidiaries as guarantors party thereto, the lenders party thereto, or the Lenders, and Sixth Street Lending Partners, as the administrative agent and collateral agent for the Lenders. The Financing Agreement provides for a senior secured term loan facility of up to $500 million, or the Credit Facility, consisting of (i) an initial draw of $100 million on the Closing Date, (ii) a potential additional $100 million draw upon the acceptance by the FDA of our BLA submission for risto-cel prior to a certain date, or the Delayed Draw A, (iii) a potential additional $100 million draw at the Company’s option upon the FDA’s approval of the risto-cel BLA prior to a certain date, or the Delayed Draw B, (iv) a potential additional $100 million draw at the Company’s option upon achieving a revenue target from sales of risto-cel prior to a certain date and (v) a potential additional $100 million draw subject to agreement among us and the Lenders. The Credit Facility matures on February 24, 2033, or the Maturity Date, and bears interest at an annual rate equal to the 3-month Secured Overnight Financing Rate (SOFR) plus 6.50% (subject to a 1.00% floor) or permits interest on a base rate plus a margin. Certain additional commitment, administrative, undrawn amount and facility fees are also payable in connection with the Credit Facility.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
The Credit Facility requires quarterly interest payments, but does not provide for scheduled amortization payments during the term. All principal will be due on the Maturity Date. We will have the right to prepay loans under the Credit Facility at any time. We are required to repay loans under the Credit Facility with proceeds from certain asset sales and licensing transactions, condemnation events and extraordinary receipts, subject, in some cases, to reinvestment rights. Repayments are subject, in some cases, to prepayment premiums.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
All obligations under the Financing Agreement will be secured on a first-priority basis, subject to certain exceptions, by security interests in substantially all assets of us and our material subsidiaries, including our intellectual property, and will be guaranteed by our material subsidiaries, subject to certain exceptions.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RemovedMD&A
In parallel with Wave 1 development, we also aim to improve the transplant conditioning regimen for patients undergoing HSCT, thereby reducing toxicity challenges associated with HSCT. Conditioning is a critical component necessary to prepare a patient’s body to receive the ex vivo edited cells that must engraft in the patient’s bone marrow in order to be effective. However, current conditioning regimens rely on nonspecific chemotherapy or radiation, which are associated with significant toxicities. As a potential alternative to genotoxic conditioning regimens in HSCT, we are advancing our ESCAPE program. ESCAPE aims to avoid toxicity challenges associated with currently available conditioning regimens for patients with sickle cell disease and beta-thalassemia ahead of autologous HSCT, by combining antibody-based conditioning with multiplex gene edited HSCs. ESCAPE may also have applications in other diseases of the blood and immune system where HSCT could deliver potential benefits but has been limited by toxicities associated with current standard of care conditioning regimens.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
We have nominated a development candidate for our ESCAPE technology comprised of two investigational drug products: BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy that includes the same therapeutic edit as BEAM-101 (editing the HBG1/2 genes to elevate fetal hemoglobin), plus an additional edit to CD117 designed to block binding of BEAM-103, allowing the edited cells to evade suppression by the antibody. We intend to advance BEAM-103 and BEAM-104 for development in sickle cell disease and beta-thalassemia, potentially building on the same regulatory, manufacturing, clinical and commercial foundations being established with BEAM-101. We expect to initiate a Phase 1 healthy volunteer clinical trial of BEAM-103 by the end of 2025.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
We are also exploring the potential for in vivo base editing programs for sickle cell disease, in which base editors would be delivered to the patient through an infusion of LNPs targeted to HSCs, eliminating the need for transplantation altogether. This approach could provide a more accessible option for patients, particularly in regions where ex vivo treatment is challenging.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
•A decrease of $38.8 million in other expense primarily due to decreases of accrued liabilities for estimated license fees associated with the Lilly transaction; and
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
•A decrease of $16.9 million attributable to the settlement of a contingent liability;
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RewordedMD&A
These uses of cash were partially offset by increases in other liabilities of $7.7 million and accounts payable of $1.8 million $6.0 million, a decrease in prepaid expenses and other long-term liabilities current assets of $0.5 $4.5 million, as well as noncash items, including stock-based compensation expense of $120.7 $94.2 million, depreciation and amortization expense of $21.9 $22.3 million, a decrease in the fair value of non-controlling equity investments of $14.1 million and a decrease in operating lease right-of-use, or ROU, assets of $9.7 million. $10.4 million and a realized loss of $0.4 million on our sale of marketable securities.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
For the year ended December 31, 2024, 2025, cash provided by used in investing activities of $185.0 $121.4 million was primarily the result of driven by net maturities purchases of marketable securities partially offset by purchases of marketable securities, in addition to $367.3 million, purchases of property and equipment of $8.9 million. $15.0 million and the payment of $0.1 million of equity issuance costs associated with our acquisition of an early-stage life sciences company.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Years Year Ended December 31, 2025 2024 2023 Change External research and development expenses $ 142,376 $ 114,473 $ 154,178 $ (39,705) 27,903 Employee related expenses 117,366 98,796 109,878 (11,082) 18,570 Facility and information technology related expenses 77,146 73,387 69,339 4,048 3,759 Stock-based compensation expense expenses 56,123 73,522 57,812 15,710 (17,399) In-process research and development expenses 14,507 — 14,507 Other expense (income) expenses 2,100 7,383 46,174 (38,791) (5,283) Total research and development expenses $ 409,618 $ 367,561 $ 437,381 $ (69,820) 42,057
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash provided by financing activities for the year ended December 31, 2024 2025 of $7.7 $478.0 million consisted of $470.5 million of proceeds from the March 2025 issuance of common stock and pre-funded warrants, $4.7 million of proceeds from the exercise of stock options of $5.6 million and $2.6 $2.8 million of proceeds from the issuance of common stock under our Employee Stock Purchase Plan, or ESPP, offset in part by net repayments of equipment financing liabilities of $0.5 million. ESPP.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
During the years ended December 31, 2024 2025 and 2023, 2024, we recorded $1.6 $0.2 million and $9.7 $1.6 million, respectively, of other income related to the change in fair value of the Guide technology and product milestone payments related to our contingent consideration liabilities as a result of an update in project timelines and the expected probability of achievement of the milestones. from acquisitions.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash used in operating activities for the year ended December 31, 2024 2025 was $347.2 $345.1 million, including our net loss of $376.7 $80.0 million, decreases in accrued expenses and other liabilities of $57.7 million, deferred revenue of $36.5 million and $135.4 million, operating lease liabilities of $13.0 million, and an increase in prepaid expenses $13.5 million and other current assets long-term liabilities of $5.4 $0.3 million.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
In addition, noncash items, including the gain on sale of equity method investment of $255.1 million, amortization of investment discounts and premiums of $22.8 $16.0 million, decreases an increase in the fair value of non-controlling equity investments of $3.9 million, a decrease in the fair value of derivative liabilities of $2.3 $0.7 million and a change in the fair value of contingent consideration liabilities of $1.6 $0.2 million, also contributed to net cash used in operating activities.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
License and collaboration revenue was approximately $139.7 million for the year ended December 31, 2025, compared to approximately $63.5 million for the year ended December 31, 2024, compared to approximately $377.7 million for the year ended December 31, 2023, a decrease an increase of $314.2 $76.2 million.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
License and collaboration revenue recorded in 2024 2025 represents revenue recorded under the Pfizer, Apellis and Orbital Agreements, as well as $27.0 million of revenue recognized from development and regulatory milestones achieved under our agreements with Lilly and Sana. Agreements.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Debt financing, if available, may involve agreements that include The Financing Agreement includes covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. dividends, and future debt financings, if available, may include similar restrictions.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
During the year ended December 31, 2024, 2025, we recorded $2.3 $0.7 million of other income related to the change in fair value of the derivative liabilities as compared to $7.5 $2.3 million for the year ended December 31, 2023, 2024, driven primarily by the decline in the price of our common stock. a declining interest rate enviornment.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease increase in revenue is driven primarily by $216.4 $109.1 million of up-front revenue recognized in the year ended December 31, 2023, from 2025, due to the transaction completion of our collaboration deal with Lilly (see Note 10) Pfizer and the net change in activity amongst our other collaboration agreements.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new